Singapore, March 28 -- The Chinese University of Hong Kong's (CUHK) Faculty of Medicine (CU Medicine) has created the first Asian population-based bladder cancer patient-derived organoid biobank, which not only offers new hope for precision treatment to bladder cancer patients in Hong Kong but also marks a significant milestone in oncology research in Asia.

Bladder cancer is a major urological disease and among the top 10 most common cancers in the world. It is mainly divided into non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), which have different molecular features. The disease is prone to metastasis and recurrence, posing challenges to clinical treatment.

Surgery and chemotherapy are first-line t...